Oncology
AP-101
Target
VEGF-A × DLL4 bispecific
Indication
Colorectal carcinoma
Discovery
Preclinical
IND
Phase I
Phase II
Research pipeline
Five programs. One vascular platform.
Each candidate is built on a shared bispecific scaffold — accelerating discovery and de-risking development.
Program matrix
Research-stage portfolio
Stages are directional planning markers and do not imply regulatory clearance or clinical readiness.
Oncology
AP-104
Target
VEGF-C inhibitor
Indication
Non-small cell lung cancer
Discovery
Preclinical
IND
Phase I
Phase II
Ophthalmology
AP-220
Target
Long-acting anti-VEGF
Indication
Wet AMD
Discovery
Preclinical
IND
Phase I
Phase II
Cardiovascular
AP-305
Target
Pro-angiogenic mRNA
Indication
Ischemic heart disease
Discovery
Preclinical
IND
Phase I
Phase II
Inflammation
AP-410
Target
VEGF / Ang-2
Indication
Diabetic retinopathy
Discovery
Preclinical
IND
Phase I
Phase II
Want the detailed data package?
Available to qualified partners under NDA.